Neoadjuvant With T1 Plus Immuno-chemotherapy for Resectable NSCLC
Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This study aims to explore the efficacy and safety of thymosin -1 (T1) plus chemotherapy and PD-1 inhibitors as neoadjuvant therapy for operable non-small cell lung cancer